Substrate for CYP 2C9. Occasional clinical experience of non-porphyrinogenicity.

(To be edited, initial data ST OCT 04) Angiotensin II receptor antagonist. Biovailability 60 - 80 %; metabolized by CYP 2C9. Less potent inhibitor of CYPs 1A2, 2C9, 3A4. Thunell, patient report (n=1): tolerated. Andersson, patient report (n=1): tolerated French list: avoid.

Uneventful use reported in 10 patients with acute porphyria.